EU/3/10/760: Orphan designation for the treatment of ovarian cancer
(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosilate monohydrate salt (niraparib)
Table of contents
Overview
On 4 August 2010, orphan designation (EU/3/10/760) was granted by the European Commission to Merck Sharp & Dohme Limited, United Kingdom, for (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt (also known as MK-4827) for the treatment of ovarian cancer. (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt has been authorised in the EU as Zejula since 16 November 2017.
This medicine is now known as niraparib.
The sponsorship was transferred to Tesaro U.K. Limited, United Kingdom, in December 2012.
The sponsorship was transferred to TESARO Bio Netherlands B.V. in December 2018.
The sponsorship was transferred to GlaxoSmithKline (Ireland) Limited., Ireland, in December 2019.
Key facts
Active substance |
(3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosilate monohydrate salt (niraparib)
|
Intended use |
Treatment of ovarian cancer
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/10/760
|
Date of designation |
04/08/2010
|
Sponsor |
GlaxoSmithKline (Ireland) Limited |
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Zejula at the time of change to the terms of the marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the
orphan medicine assessment report
.
During its meeting of 3 to 5 October 2017, the Committee for Orphan Medicinal Products (COMP) reviewed the designation EU/3/10/760 for Zejula (niraparib1) as an orphan medicinal product for the treatment of ovarian cancer. The COMP assessed whether, at the time of marketing authorisation, the medicinal product still met the criteria for orphan designation. The Committee looked at the seriousness and prevalence of the condition, and the existence of other methods of treatment. As other methods of treatment are authorised in the European Union (EU), the COMP also considered whether the medicine is of significant benefit to patients with ovarian cancer.The COMP recommended that the orphan designation of the medicine be maintained2.
1 Previously known as (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt.
2The maintenance of the orphan designation at time of marketing authorisation would, except in specific situations, give an orphan medicinal product 10 years of market exclusivity in the EU. This means that in the 10 years after its authorisation similar products with the same therapeutic indication cannot be placed on the market.
Recommendation for maintenance of orphan designation at the time of marketing authorisation: Zejula (niraparib) for the treatment of ovarian cancer (PDF/70.82 KB)
First published: 04/12/2017
Last updated: 04/12/2017
EMA/712784/2017
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: